Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v2-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated | 2026-02-27 | 2026-02-27 |
| Drug Identification Number | 02357631 | 02357631 |
| Brand name | VIMPAT | VIMPAT |
| Common or Proper name | Vimpat 150mg tablets | Vimpat 150mg tablets |
| Company Name | UCB CANADA INC | UCB CANADA INC |
| Ingredients | LACOSAMIDE | LACOSAMIDE |
| Strength(s) | 150MG | 150MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 60 | 60 |
| Additional packaging sizes | ||
| ATC code | N03AX | N03AX |
| ATC description | ANTIEPILEPTICS | ANTIEPILEPTICS |
| Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
| Anticipated start date | 2026-03-06 | 2026-03-06 |
| Actual start date | ||
| Estimated end date | 2026-03-20 | 2026-03-20 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Short terms OOS. Product ready to ship from USA. Will ship as soon as DEA export approval is received. | Short terms OOS. Product ready to ship from USA. Will ship as soon as DEA export approval is received. |
| Health Canada comments |